BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 28745687)

  • 1. [Nephrological aspects of complement-mediated thrombotic microangiopathy].
    Smirnov AV; Karunnaya AV; Dobronravov VA
    Ter Arkh; 2017; 89(6):34-40. PubMed ID: 28745687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre.
    Grall M; Daviet F; Chiche NJ; Provot F; Presne C; Coindre JP; Pouteil-Noble C; Karras A; Guerrot D; François A; Benhamou Y; Veyradier A; Frémeaux-Bacchi V; Coppo P; Grangé S
    BMC Nephrol; 2021 Jul; 22(1):267. PubMed ID: 34284729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
    Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
    Legendre CM; Licht C; Muus P; Greenbaum LA; Babu S; Bedrosian C; Bingham C; Cohen DJ; Delmas Y; Douglas K; Eitner F; Feldkamp T; Fouque D; Furman RR; Gaber O; Herthelius M; Hourmant M; Karpman D; Lebranchu Y; Mariat C; Menne J; Moulin B; Nürnberger J; Ogawa M; Remuzzi G; Richard T; Sberro-Soussan R; Severino B; Sheerin NS; Trivelli A; Zimmerhackl LB; Goodship T; Loirat C
    N Engl J Med; 2013 Jun; 368(23):2169-81. PubMed ID: 23738544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement-mediated thrombotic microangiopathy treated with anticomplement protein 5 therapy, a retrospective study.
    Laber DA; Patel PC; Logothetis CN; Patel AK; Jaglal M; Haider M; Visweshwar N; Rajasekaran-Rathnakumar G; Eatrides J
    Eur J Haematol; 2024 Mar; 112(3):450-457. PubMed ID: 37984551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
    Schoettler M; Lehmann L; Li A; Ma C; Duncan C
    Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
    Fakhouri F; Delmas Y; Provot F; Barbet C; Karras A; Makdassi R; Courivaud C; Rifard K; Servais A; Allard C; Besson V; Cousin M; Châtelet V; Goujon JM; Coindre JP; Laurent G; Loirat C; Frémeaux-Bacchi V
    Am J Kidney Dis; 2014 Jan; 63(1):40-8. PubMed ID: 24021908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
    Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC.
    de Fontbrune FS; Galambrun C; Sirvent A; Huynh A; Faguer S; Nguyen S; Bay JO; Neven B; Moussi J; Simon L; Xhaard A; Resche-Riggon M; O'Meara A; Fremeaux-Bacchi V; Veyradier A; Socié G; Coppo P; de Latour RP
    Transplantation; 2015 Sep; 99(9):1953-9. PubMed ID: 25651309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombotic microangiopathy associated with monoclonal gammopathy.
    Ravindran A; Go RS; Fervenza FC; Sethi S
    Kidney Int; 2017 Mar; 91(3):691-698. PubMed ID: 27998645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab.
    El-Husseini A; Hannan S; Awad A; Jennings S; Cornea V; Sawaya BP
    Am J Kidney Dis; 2015 Jan; 65(1):127-30. PubMed ID: 25446020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement Activation and Thrombotic Microangiopathy Associated With Monoclonal Gammopathy: A National French Case Series.
    Martins M; Bridoux F; Goujon JM; Meuleman MS; Ribes D; Rondeau E; Guerry MJ; Delmas Y; Levy B; Ducloux D; Kandel-Aznar C; Le Fur A; Garrouste C; Provot F; Gibier JB; Thervet E; Bruneval P; Rabant M; Karras A; Dragon Durey MA; Fremeaux-Bacchi V; Chauvet S
    Am J Kidney Dis; 2022 Sep; 80(3):341-352. PubMed ID: 35217094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
    Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinine-Induced Thrombotic Microangiopathy: A Report of 19 Patients.
    Page EE; Little DJ; Vesely SK; George JN
    Am J Kidney Dis; 2017 Nov; 70(5):686-695. PubMed ID: 28780041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.
    de Holanda MI; Pôrto LC; Wagner T; Christiani LF; Palma LMP
    Clin Rheumatol; 2017 Dec; 36(12):2859-2867. PubMed ID: 28905254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab.
    Shochet L; Kanellis J; Simpson I; Ta J; Mulley W
    Nephrology (Carlton); 2017 Feb; 22 Suppl 1():23-27. PubMed ID: 28176480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathology Consultation on the Diagnosis and Treatment of Thrombotic Microangiopathies (TMAs).
    Williams LA; Marques MB;
    Am J Clin Pathol; 2016 Feb; 145(2):158-65. PubMed ID: 27124904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension.
    Timmermans SAMEG; Abdul-Hamid MA; Potjewijd J; Theunissen ROMFIH; Damoiseaux JGMC; Reutelingsperger CP; van Paassen P;
    J Am Soc Nephrol; 2018 Aug; 29(8):2234-2243. PubMed ID: 29858281
    [No Abstract]   [Full Text] [Related]  

  • 19. Association of Serum C3 Concentration and Histologic Signs of Thrombotic Microangiopathy with Outcomes among Patients with ANCA-Associated Renal Vasculitis.
    Manenti L; Vaglio A; Gnappi E; Maggiore U; Allegri L; Allinovi M; Urban ML; Delsante M; Galetti M; Nicastro M; Pilato FP; Buzio C
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2143-51. PubMed ID: 26542163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombotic microangiopathy in a patient with adult-onset Still's disease.
    Rawal S; Einbinder Y; Rubin L; Perl J; Trinkaus M; Teitel J; Pavenski K
    Transfusion; 2014 Nov; 54(11):2983-7. PubMed ID: 24845532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.